Description

The life sciences IPO market has faced significant headwinds in recent years, but signs of a potential reopening in the capital markets are emerging. As investor sentiment shifts and regulatory landscapes evolve, biotech and healthcare companies must be strategic in their approach to going public. We’ll bring together industry experts to discuss the latest trends, key considerations for IPO readiness, and what it takes to successfully access public markets in today’s environment.

Register Now